G
roup A streptococcus (GAS) infection can cause a delayed autoimmune response manifesting as acute rheumatic fever (ARF), and repeated GAS infections can culminate in autoimmune-driven rheumatic heart disease (RHD). Recent data estimate the current global prevalence of RHD at 33.4 million cases, with 319 000 deaths each year. 1 The burden of RHD remains particularly high in the Australian Indigenous population. 2 The major autoimmune manifestation of RHD is progressive cardiac valve dysfunction, which can be complicated by cardiac failure, arrhythmia, and thromboembolism. Nonsteroidal antiinflammatory drugs and glucocorticoids provide symptomatic relief in ARF, but they do not prevent RHD. 3 Monthly penicillin injections for ≥10 years after ARF is currently the only effective strategy for preventing recurrent ARF and progression to RHD in at-risk individuals, but this regimen can be difficult to implement and sustain.
Although the pattern-recognition mechanism by which human immune cells sense GAS antigens is not completely understood, peptidoglycans, nucleic acids, and M proteins from GAS can activate macrophages to produce proinflammatory cytokines, such as interleukin (IL)-1β and tumor necrosis factor (TNF). [4] [5] [6] [7] After antigenspecific activation by antigen-presenting cells, naïve CD4 T cells differentiate into effector populations that shape the host immune response, namely, T helper (Th) 1, Th2, and Th17 subsets, with characteristic cytokine, surface receptor, and transcription factor profiles. 8 Molecular mimicry is widely regarded as the basis for ARF, including the activation of CD4 T cells specific for streptococcal antigens, most likely M protein, that cross-react with host cardiac antigens and are thought to cause valvulitis. 9, 10 Protein-reactive T cells accumulate within cardiac valves in the Lewis rat model of rheumatic carditis. 11 In RHD, excised valvular tissue contains T cells producing interferon (IFN) γ, a cytokine typically made by Th1 cells, which suggests that these autoreactive cells are Th1 polarized. 12, 13 T-cell reactivity against GAS antigens in the peripheral blood is thought to mirror reactivity of heartinfiltrating T cells in patients with RHD, 14 but relatively little is known about how GAS shapes the CD4 T cell responses that ultimately lead from ARF to RHD.
To better understand cellular autoimmunity in ARF and RHD, we analyzed immune responses to GAS in peripheral blood mononuclear cells (PBMC) from patients with ARF. Aboriginal patients with ARF and Aboriginal healthy controls (AHC) were recruited from the Northern Territory of Australia, where Indigenous Australians are much more likely than non-Indigenous people to develop a first episode of ARF and to die from ARF/RHD. 15 In this clinically well-characterized cohort of patients with ARF, we report that PBMC immune responses to GAS are dysregulated, leading to overproduction of CD4 T cell-derived proinflammatory cytokines, including granulocyte-macrophage colony-stimulating factor (GM-CSF). Increased production of CD4 T cell-derived cytokines, especially in those with existing RHD, was closely associated with persistently elevated IL-1β. IL-1β was rapidly released from PBMC in both patients with ARF and AHC on day 1 of culture with GAS. By day 4, this declined markedly in AHC but not in ARF PBMC. Furthermore, IL-1β positively regulated expansion of a GM-CSF-expressing subset of Th1 CD4 T cells. Consistent with previous reports of CXCR3-positive Th1 cells in the valvular lesions of patients with RHD, 12,13 CXCL10, a CXCR3 ligand and potent Th1 chemoattractant, was significantly elevated in the plasma of patients with ARF compared with AHC. Analysis of gene expression by RNA sequencing (RNAseq) was performed on PBMCs from individual patients admitted to hospital with ARF (ARF1) and then when these patients recovered (ARF2). This revealed disease-related inflammatory gene expression in ARF that subsided with recovery. Among 103 upregulated genes in the pathway of myeloid leukocyte activation in ARF1 compared with ARF2, 11 genes were also significantly induced by GAS stimulation of PBMC in vitro.
T cell-derived GM-CSF plays a pivotal role in the progression of autoimmune diseases such as rheumatoid
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What Is New?
• Group A streptococcus activates persistent interleukin-1β production, selective expansion of CXCR3 + CCR4 − CCR6 − CD4 Th1 cells, and overproduction of granulocyte-macrophage colony-stimulating factor in peripheral blood mononuclear cells from patients with ARF in vitro.
• Interferon γ-induced protein 10, which is a Th1 chemoattractant also known as CXCL10, was elevated in the plasma of Aboriginal patients with acute rheumatic fever compared with Aboriginal healthy controls.
• Hydroxychloroquine limits the expansion of these group A streptococcus-activated, granulocytemacrophage colony-stimulating factor-producing Th1 cells in vitro.
• Gene transcriptional profiling of peripheral blood mononuclear cells from patients with acute rheumatic fever shows dynamic changes at different stages of disease.
What Are the Clinical Implications?
• Hydroxychloroquine is inexpensive, it has been used for decades to treat autoimmune disorders, and its safety profile is well established.
• These features make hydroxychloroquine particularly attractive as an adjunctive therapy, in addition to secondary prevention measures, for populations where rates of acute rheumatic fever and rheumatic heart disease remain high. 
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arthritis (RA), multiple sclerosis (MS), and autoimmune myocarditis. 16, 17 GM-CSF-expressing CD4+ T cells are important because GM-CSF links innate (myeloid cells) and adaptive (lymphocyte) immunity in autoimmune diseases and GM-CSF blockade has been proposed to have therapeutic effect on multiple autoimmune diseases. 18, 19 The expansion of GM-CSF-expressing CD4 T cells was effectively suppressed by a clinically relevant dose of hydroxychloroquine (HCQ). Given the wellknown safety profile of HCQ, which has been used for decades to treat autoimmune diseases such as RA and systemic lupus erythematosus, we propose that HCQ could be repurposed as an immunomodulatory agent to reduce the risk of RHD after ARF.
METHODS
The analytic methods will be made available to other researchers for the purposes of replicating procedures from the corresponding author on request. However, gene expression analysis from individual patients will not be made available. 20 To ensure ethnicity-matched groups, ARF and control groups were exclusively comprised of Aboriginal participants. Peripheral blood was obtained at diagnosis of ARF-usually within 7 days of admission to hospitaland then on discharge from hospital (usually 1 or 2 weeks later). 
Ethical Approval and Study Participants

Streptococcus pyogenes (GAS) Strains
A cocktail of heat-killed GAS comprised of 3 strains isolated from ARF cases in the NT (Strain NS52, M type 218; Strain NS702.2, M type 65; Strain NS1713, M type 53) was used for all experiments. GAS was grown at 37°C in Todd-Hewitt broth (BD Biosciences), with 5% yeast extract (BD Biosciences) and washed twice before heat killing at 60˚C for 1 hour.
PBMC Isolation, Th Cell Differentiation, and Expansion
PBMCs were isolated using Ficoll-Paque density gradient medium (GE Healthcare) and LeucoSep tubes (Greiner BioOne) according to the manufacturer's instructions; 2x10 5 PBMCs were cultured in IMDM+5% human AB serum (Sigma) with heat-killed GAS (multiplicity of infection, MOI 0.5) in 96-well flat bottom plates for 1 or 4 days, and the supernatants were collected for measurement of cytokines. Cultures were then supplemented with IL-2 (10 U/mL, R&D Systems) for ≤9 days, after which cells were analyzed by flow cytometry.
Measurement of Cytokines
Cytokines and chemokines were measured using Bio-Plex Pro Human Cytokine 27-Plex (BIO-RAD) or Milliplex MAP bead arrays (Abacus ALS).
Isolation and Stimulation of CD14+ Monocytes
CD14+ monocytes were isolated from PBMC using a Monocyte Isolation Kit II (Miltenyi Biotec); 1x10 5 /well CD14+ monocytes were stimulated with heat-killed GAS (MOI 1) for 20 hours. TNF (BD) and IL-1β (PeproTech) were measured by specific ELISA.
Flow Cytometry
Antibodies to human antigens were as follows: BD Biosciences: 
RNAseq
RNA samples were sequenced on an Illumina HiSeq 2000. Reads were aligned using Rsubread 21 and differential expression analyses conducted using the limma software package. 22 Further details are given in the online-only Data Supplement.
Statistical Analyses
Statistical analysis was performed using Prism 7 (GraphPad). Unpaired t test (2-tailed) with Welch's correction was used to compare 2 participant groups. Two-way ANOVA (paired) with Sidak's multiple comparisons test was used for characterization of in vitro responses. Paired t test (2-tailed) was used to compare paired measurements. Data are summarized as mean±SEM or SD for biological replicates or technical replicates, respectively.
RESULTS
RNAseq Analysis of GAS-Induced Gene Expression and Multiplex Cytokine Analysis in PBMC From HVDs
We reasoned that because ARF is a delayed sequel to previous GAS infection, immune responses to rheu-matogenic but nonviable GAS would be informative.
We therefore performed RNAseq to analyze mRNA expression changes in PBMC from HVDs, stimulated in vitro with heat-killed GAS for 24 hours. We found 2970 differentially expressed genes (DEGs), of which 1578 genes were upregulated and 1392 downregulated (by false discovery rate or false discovery rateadjusted P value<0.05, data not shown). Among those DEGs, the top 50 most upregulated genes by average log-fold change from 3 HVDs included proinflammatory cytokines, chemokines, and many IFNstimulated genes ( Figure 1A ). TLR8-dependent detection of bacterial RNA has recently been shown to be critical for triggering human monocyte activation and
Figure 1. RNAseq and cytokine analysis of the PBMC response to heat-killed GAS in healthy volunteer donors (HVDs).
A, Heat map showing GAS-induced gene expression in PBMC from 3 HVDs. Shown are the top 50 genes most upregulated by GAS with log2-fold changes (logFC) and false discovery rates (FDRs). B, Expression changes of TLR family genes after GAS stimulation of PBMC. C, Secretion of IL-1β and TNF from PBMC 24 hours after stimulation with GAS. *P<0.05; *** P<0.005 by paired t test (2-tailed). D, Secretion of IL-1β and TNF from isolated CD14+ monocytes 20 hours after stimulation with GAS. Error bars=mean±SEM, 3 technical replicates. GAS indicates group A streptococcus; IL, interleukin; PBMC, peripheral blood mononuclear cell; RNAseq, RNA sequencing; and TNF, tumor necrosis factor. A and B, Secretion of cytokines from PBMC-AHC (circle, N=4) and ARF (square, N=10)-was measured on day 1 (A) and day 4 (B) after PBS or GAS stimulation by MILLIPLEX Multiplex assays. C, Concentration of IL-1β from the AHC group (left) or the ARF group (right) was compared between day 1 (circle) and day 4 (square). Error bars=mean±SEM. D, Correlation between IL-1β and GM-CSF level (pg/mL) measured on day 4 after GAS stimulation of ARF PBMCs. Gray circles highlight ARF patients with a previous history of RHD compared to those with no history of RHD (black circles). AHC indicates Aboriginal healthy control; ARF, acute rheumatic fever; GAS, group A streptococcus; GM-CSF level, granulocyte-macrophage colony-stimulating factor; IL, interleukin; PBMC, peripheral blood mononuclear cell; PBS, phosphate buffered saline; and RHD, rheumatic heart disease. ORIGINAL RESEARCH ARTICLE production of proinflammatory cytokines in response to GAS. 5 The expression of Toll-like receptor 8 (TLR8) along with TLR2, TLR3, and TLR7 was also upregulated after GAS stimulation of PBMC ( Figure 1B ). High levels of IL-1β and TNF secretion were found with GAS stimulation of PBMCs for 24 hours, in keeping with increased transcription, well illustrated by donor 3 ( Figure 1C ). IL-1β and TNF secretion were also evident in response to GAS stimulation of CD14+ monocytes isolated from PBMC ( Figure 1D ), suggesting that monocytes may be the primary source of IL-1β and TNF production in PBMC. IFNγ (161.4±26.0 pg/mL), IL-10 (139.6±20.3 pg/mL), and GM-CSF (62.3±19.0 pg/mL) were also secreted, whereas the Th2 cytokine IL-4 (10.0±1.43 pg/mL) and the Th17 cytokine IL-17A (26.3±1.7 pg/mL) were released at much lower levels over this period. These in vitro results support the Th1-skewed immune profiles found in the valvular lesions of patients with RHD, and they also reveal previously uncharacterized immune responses to GAS, including the production of GM-CSF.
Enhanced GM-CSF Production Associated With Persistent IL-1β Release in ARF PBMCs Cultured With GAS
To determine whether PBMC responses to GAS might be abnormal in patients with ARF, we compared cytokine production from 4 AHC and 10 patients with ARF at days 1 and 4 of in vitro culture. GAS-induced cytokine secretion at day 1 was similar between AHC and patients with ARF, suggesting little difference in the initial innate immune response to GAS in patients with ARF ( Figure 2A ). However, less IFNγ was produced in the ARF group (0.7±0.2 ng/mL) compared with AHC (3.4±0.8 ng/mL) ( Figure 2A ). In contrast, on day 4, when antigen-specific CD4 T cells become activated, the levels of TNF, IL-17F and GM-CSF ( Figure 2B ) were elevated in patients with ARF compared to AHC ( Figure 2B ). Among these differentially secreted cytokines, GM-CSF was of particular interest given its key pathogenic role in many autoimmune diseases, including autoimmune myocarditis. 16 Because it was shown previously that GM-CSF production by CD4 T cells is positively regulated by IL-1 signaling, 23 we speculated that elevated GM-CSF in patients with ARF at day 4 may be because of dysregulated production of IL-1β. Notably, when the level of IL-1β was compared between days 1 and 4, it was markedly downregulated in all AHCs ( Figure 2C ). In contrast, in some patients with ARF, these reductions were absent or much less prominent, resulting in persistent secretion of IL-1β ( Figure 2C ). Furthermore, a strong positive correlation between the levels of IL-1β and GM-CSF was seen in ARF samples. It is interesting to note that 4 out 10 patients with ARF (patients 1, 2, 8, and 10; 9 to 21 years of age) had RHD previously and were among the highest GM-CSF producers, associated with persistent IL-1β release ( Figure 2D and Table) . Three young patients with ARF (patients 1, 2, 8, and 10; 9 to 21 years of age) also showed much higher IL-1β/GM-CSF responses to GAS compared with AHC, similar to those who had RHD previously. Thus, we speculate that a dysregulated IL-1β-GM-CSF immune axis after recurrent GAS infection might be a risk factor for the progression from ARF to RHD.
RNAseq Analysis of PBMC From Patients With ARF
Initial studies showed surprisingly wide variations in gene expression in the PBMC of Aboriginal healthy subjects, making them difficult to use as controls. We therefore evaluated gene expression changes in vivo . a indicates a patient sample that was also used in in vitro GAS stimulation experiments. C, Gene ontology (GO) pathway analysis with 864 DEGs. D, List of GAS-induced genes in the pathway of myeloid leukocyte activation (GO 0002274) that are also upregulated in ARF1 compared with ARF2. ANPEP indicates alanyl aminopeptidase; ARF, acute rheumatic fever; BP, biological process; CFP, complement factor properdin; DEG, differentially expressed gene; F2RL1, F2R-like trypsin receptor 1; FCGR2A, Fc fragment of IgG receptor IIa; FCGR2B, Fc fragment of IgG receptor IIb; GAS, group A streptococcus; LYN, LCK/YES novel tyrosine kinase; Ont, ontology; PBMC, peripheral blood mononuclear cell; PBS, phosphate buffered saline; PPBP, proplatelet basic protein; RNAseq, RNA sequencing; S100A9, S100 calcium binding protein A9; t, t statistic; TNF, tumor necrosis factor; and TNFAIP6, TNF-α induced protein 6.
Circulation. ORIGINAL RESEARCH ARTICLE (ie, without GAS stimulation in vitro) by performing a transcriptomic analysis of PBMCs in a subset of 4 patients with ARF for whom we had serial blood samples obtained during the hospital admission for ARF (ARF1) and also when they were well enough to be discharged from hospital (ARF2). A multidimensional scaling plot of the RNAseq data showed that ARF1 and ARF2 samples clustered in their respective groups once a correction for a patient effect was applied ( Figure 3A) . A total of 865 genes (526 upregulated and 338 downregulated) were differentially expressed in PBMC from ARF1 compared with ARF2 ( Figure 3B ). Pathway analysis by gene ontology (GO) terms showed that upregulated genes in ARF1 compared with ARF2 were most enriched in the pathways of leukocyte degranulation (GO 0043299), regulated exocytosis (GO 0045055), and myeloid leukocyte activation (GO 0002274) (Figure 3C ), consistent with disease-related inflammatory gene expression at ARF1, with ARF2 reflecting a return toward baseline. Among 103 upregulated genes in the pathway of myeloid leukocyte activation (GO 0002274) in ARF1 compared with ARF2, 11 genes (proplatelet basic protein, F2R-like trypsin receptor 1, Fc fragment of immunoglobulin G receptor IIa, TNF-α induced protein 6, complement factor properdin, CXCL1, CD14, Fc fragment of immunoglobulin G receptor IIb, S100 calcium binding protein A9, alanyl aminopeptidase, and LCK/YES novel tyrosine kinase), were also significantly induced by GAS stimulation of PBMC in vitro ( Figure 3D ). These genes all have plausible links to the immunopathogenesis of ARF. In addition, MYD88 and caspase 1, which are important for IL-1β expression and processing, respectively, were also upregulated in ARF1 samples but subsided during recovery (data not shown).
Abnormal Expansion of GAS-Induced Th1 Cells and Elevated Plasma IFNγ-Induced Protein 10 in ARF PBMC
T cell recruitment to valvular tissue lesions of patients with chronic RHD may be mediated by ligands for CXCR3. 24 It was previously shown that CXCR3-positive Th1 cells are the major source of human CD4 T cell-derived GM-CSF. 25 To further characterize abnormal CD4 T cell response to GAS in patients with ARF, we used a flow cytometric approach to profile cell surface expression of chemokine receptors on CD4 T cells after initial 4-day GAS stimulation, followed by the expansion of activated T cells with IL-2. Differential surface expression of CXCR3, CCR4, CCR6, and CRTH2 has been used to define human CD4 subsets as Th1 (CXCR3 Figure 4A ). 26, 27 We found that the frequency of Th1 cells was selectively increased in patients with ARF compared with AHC ( Figure 4B ), whereas neither Th2 nor Th17 frequency was significantly changed (Figure 4C and 4D) . To further investigate potential inflammatory mediators, we performed a multiplex cytokine/chemokine assay on plasma from patients with ARF and AHC. We could not detect most cytokines or chemokines, including IL-1β, IFNγ, and GM-CSF, suggesting these are not elevated 
ORIGINAL RESEARCH ARTICLE
in the systemic circulation of patients with ARF. In contrast, IFNγ-induced protein 10, also known as CXCL10, which is a potent Th1 chemoattractant, was abundant in plasma and significantly elevated in patients with ARF compared with AHC ( Figure 4E , Table I 
GAS-Induced Differentiation of GM-CSF-Expressing CD4 T Cells by an IL-1β-Independent Mechanism
Whether GAS induces differentiation of GM-CSFexpressing human CD4 T cells is currently unknown. Thus, we investigated GAS-induced differentiation of CD4 T cells in HVDs. GM-CSF-expressing CD4 T cells that mostly coexpress IFNγ (GM-CSF + IFNγ + ) were consistently, although variably, expanded after GAS priming in HVD PBMC ( Figure 5A and 5B). To further dissect the positive association between IL-1β and GM-CSF responses to GAS in PBMC from HVDs, we investigated whether neutralization of IL-1β with IL-1 receptor antagonist affected the frequency of GM-CSF-expressing CD4 T cells ( Figure 5C ). IL-1 receptor antagonist had little effect, arguing that GAS induces the initial differentiation of GM-CSF-expressing CD4 T cells in an IL-1β-independent manner in human PBMC. In contrast, IL-17A-expressing CD4 T cells (Th17) were not reproducibly induced by GAS ( Figure 5D ), and only a small proportion of GM-CSF-expressing CD4 T cells coexpressed IL-17A ( Figure 5E ). These findings, albeit from HVDs, argue that GAS-induced, GM-CSF-producing human CD4 T cells are associated with a Th1 rather than a Th17 profile. Our finding of a dominant GM-CSF-expressing Th1 response to GAS in peripheral blood concurs with Th1-skewed immune profiles in valve-infiltrating cells isolated from patients with RHD, and it raises the novel possibility that RHD belongs to a group of GM-CSF-driven autoimmune diseases.
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Figure 5. GAS-induced differentiation of Th1 cells that coexpress GM-CSF.
A and B, PBMC from HVDs were cultured with GAS for 4 days, followed by extended culture for 7 to 9 days in the presence of IL-2. A, Flow cytometric analysis of intracellular GM-CSF and IFNγ in CD4 T cells. B, Frequency of CD4 subsets from (A). Error bars=mean±SEM (N=6). **P<0.01. C, PBMC from HVDs were cultured with GAS or GAS+IL-1Ra (125 ng/mL) for 4 days, followed by extended culture for 7 to 9 days in the presence of IL-2. Flow cytometric analysis of intracellular GM-CSF and IFNγ in CD4 T cells. Error bars=mean±SEM (N=6). **P<0.01. D and E, PBMC from 5 HVDs were cultured with PBS or GAS for 4 days, followed by extended culture for 7 to 9 days in the presence of IL-2 (10 U/mL). D, The frequency of IL-17A-positive CD4 T cells was analyzed by flow cytometry. E, Frequency of IFNγ-expressing (red circle) or IL-17A-expressing (black square)/GM-CSF double-positive CD4 T cells. GAS indicates group A streptococcus; GM-CSF level, granulocyte-macrophage colony-stimulating factor; HVD, healthy volunteer donor; IFN, interferon; IL, interleukin; PBMC, peripheral blood mononuclear cell; PBS, phosphate buffered saline; and Th, T helper. 
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CD4 T Cell Expansion
HCQ is widely used to treat a number of autoimmune diseases, including RA and systemic lupus erythematosus, although its immunomodulatory effects are still not completely understood. Consistent with a previous report, 29 we confirmed that HCQ could dose dependently inhibit T cell receptor (TCR)-dependent in vitro activation and proliferation of CD4 T cells (data not shown). We then specifically tested the effect of HCQ on the differentiation and expansion of GAS-induced GM-CSF + IFNγ + CD4 T cells in PBMCs from HVDs. When HCQ was added either during ( Figure 6A ) or after 4-day GAS stimulation (Figure 6B and 6C) , the expansion of GM-CSF + IFNγ + CD4 T cells was limited, even in the presence of IL-2, suggesting an effect on T cell differentiation or proliferation. A recent study in the murine experimental autoimmune encephalomyelitis model showed that IL-1 signaling is critical for the expansion (rather than the generation) of autoreactive GM-CSF-expressing Th17 cells. 30 We therefore investigated whether IL-1β could enhance expansion of human GM-CSF-expressing CD4 T cells in PBMC. PBMC from HVDs were primed with exogenous IL-1β for 2 days and then treated with IL-2 for 5 days to expand CD4 T cells. IL-1β priming consistently increased the frequency of GM-CSF + IFNγ + CD4 T cells ( Figure 6D ). We then tested whether HCQ could reduce the selective expansion of GM-CSF-expressing CD4 T cells in response to cytokine stimulation with IL-1β alone in a TCR-independent fashion. When HCQ was added to PBMC cultures derived from HVD after priming with IL-1β, but before stimulation with IL-2, HCQ markedly inhibited TCR-independent expansion of GM-CSF + IFNγ + CD4 T cells, as measured by both frequency and absolute cell counts ( Figure 6E and 6F).
DISCUSSION
GAS induces rapid but transient IL-1β secretion in PBMC derived from HVDs, as was recently shown in mice. 31 We discovered that in patients with ARF, especially in those with existing RHD (defined as high-risk patients with ARF), in vitro exposure to GAS induced persistent production of IL-1β, implying potential dysregulation of feedback inhibitory mechanisms in patients with RHD. It was recently shown that soluble M protein, the most abundant protein on the surface of GAS, can activate the NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasome to induce IL-1β secretion in murine macrophages by an as yet unknown mechanism. 6 Dysregulated IL-1β production in PBMC from patients with ARF was coupled to elevated CD4 T cell-derived cytokine secretion, including GM-CSF. We provide evidence that IL-1β contributes to the expansion of GM-CSF-expressing CD4 T cells in a potential feed-forward mechanism. Transcriptome analysis by RNAseq revealed activation of myeloid leukocytes and differential expression of disease-related inflammatory genes in the PBMC of patients with ARF that subsided with recovery. At least some of these changes were also induced by GAS stimulation of PBMC in vitro. Many of these genes are of potential relevance to the immunopathogenesis of ARF. CD14 is a coreceptor for multiple TLRs on phagocytic cells. 32 Fc receptors bind immunoglobulin and mediate phagocytosis of immune complexes, as well as cellular activation. 33 Complement factor properdin binds to microbial surfaces and amplifies the alternate pathway of complement. 34 LCK/YES novel tyrosine kinase is a tyrosine kinase that regulates an array of signaling pathways downstream of multiple immune receptors, including TLRs. 35 Proplatelet basic protein (also called CXCL7) is a leukocyte-derived chemokine that attracts neutrophils and macrophages.
36 S100 calcium binding protein A9 is a member of the S100 protein family, which is a danger-associated molecular pattern molecule with a wide variety of proinflammatory functions and binds to TLR4 and (receptor for advanced glycation end products. 37 In addition, transcripts for MYD88 and caspase 1, which are important for IL-1β expression and processing, respectively, were also upregulated in ARF1 but subsided during recovery, which is consistent with GAS-induced, transient IL-1β secretion in PBMC in vitro.
Pathogenic roles for GM-CSF-producing CD4 T cells are well recognized in several mouse models of autoimmune diseases, such as RA, encephalomyelitis, and autoimmune myocarditis. It was recently reported that CXCR3
− CD4 T cells (classified as Th1) are actually the major source of GM-CSF in humans. 25 We found that CXCR3
− CD4 T cells (ie, GM-CSF-expressing Th1 cells) were significantly expanded in cultures of GAS-stimulated ARF PBMC compared with controls. In addition, IFNγ-induced protein 10/CXCL10, a potent chemoattractant for Th1 cells, was elevated in plasma from patients with ARF compared with healthy controls. Our data are in agreement with the Th1 skewing that was reported in T cells isolated directly from heart valve lesions in RHD.
12,13 CXCR3-positive cells have also been found in the mitral valves of most patients with RHD, implying that CXCR3-mediated recruitment and IL-1β-dependent expansion of GM-CSF-expressing CD4 T cells might contribute to chronic autoimmune valvulitis in RHD. In an in vivo model of myocarditis in mice, disease occurs in 2 stages: the first stage is proinflammatory and is dominated by Th1 responses. However, during a second phase, pathogenic Th17 cells dominate. 38 This finding, together with other reports, 39, 40 suggests it is possible that a similar evolution of Th responses may GAS induces persistent secretion of IL-1β from antigen presenting cells in high-risk ARF patients, leading to selective expansion of GM-CSF-expressing Th1 CD4 T cells, which is potently inhibited by HCQ. ARF indicates acute rheumatic fever; GAS, group A streptococcus; GM-CSF level, granulocyte-macrophage colonystimulating factor; HCQ, hydroxychloroquine; IL, interleukin; RHD, rheumatic heart disease; and Th, T helper. ORIGINAL RESEARCH ARTICLE occur over time in patients with ARF. It is also possible that GM-CSF-expressing CD4 T cells might be a unique cell type, separate from Th1 and Th17 cells. 41 Unfortunately, the current lack of a suitable mouse model for RHD limits direct experimental confirmation of a pathological role for IL-1β, GM-CSF, or CXCL10 in vivo. However, our study raises the possibility that each of these could provide a new therapeutic target in ARF. Of note, GM-CSF has been shown to be a crucial mediator of autoimmune myocarditis and a murine model of Kawasaki disease. 16, 42 How HCQ exerts its therapeutic effects on immune cells remains an intriguing question. HCQ inhibits the TLR signaling pathway in antigen-presenting cells by abrogating the interaction of various ligands with endosomal TLR7/9 or cyclic GMP-AMP synthase. [43] [44] [45] Our RNAseq results demonstrate that HCQ reduced expression of the endosomal TLRs, TLR3, TLR7, and, although less marked, TLR8, which is likely to impact downstream signaling pathways. HCQ can also inhibit intracellular calcium signaling downstream of the TCR in CD4 T cells. 29 It is important to note that we found that IL-1β-mediated expansion of GM-CSF-expressing CD4 T cells was effectively limited by a clinically relevant dose of HCQ (10 µM), 46 suggesting a previously unrecognized mode of action for HCQ. These findings, summarized schematically in Figure 7 , increase the potential clinical relevance of initiating treatment with HCQ after a diagnosis of ARF has been made. In view of the well-known safety profile of HCQ in treating autoimmune diseases (including RA, where GM-CSF plays a pivotal role in the pathogenesis), we propose that HCQ could potentially be repurposed to reduce the autoimmune responses leading from ARF to RHD, especially for high-risk patients with ARF. Although benzathine penicillin is currently used as secondary prophylaxis against recurrent infection with GAS, there are often practical difficulties in commencing or continuing parenteral benzathine penicillin every 4 weeks for ≥10 years. HCQ could dampen GASinduced host immunologic mechanisms in ARF and, in combination with benzathine penicillin secondary prophylaxis, thereby reduce the risk progression to RHD. If this proved to be the case, it would constitute the only significant advance in treatment for ARF and patients with RHD since the advent of benzathine penicillin for secondary prophylaxis more than half a century ago.
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